The role of ursodeoxycholic acid in the management of patients with non-alcoholic fatty liver disease and cardiometabolic multimorbidity: a review of current evidence
Ostroumova O.D., Kochetkov A.I., Plotnikova N.A., Dedovets E.K., Suglobova E.V.
Non-alcoholic fatty liver disease (NAFLD) is regarded as a clinical marker of systemic metabolic dysfunction and an important component of the cardiometabolic multimorbidity phenotype. The aim of this review is to summarize current evidence on the association of NAFLD with cardiovascular prognosis and disorders of carbohydrate and lipid metabolism, and to present the potential role of ursodeoxycholic acid (UDCA) in the comprehensive management of these patients. The literature search methodology included an analysis of publications indexed in PubMed/MEDLINE, Scopus, the Cochrane Library, and eLIBRARY for 2018–2026, clinical guidelines, as well as key studies from previous years. The available evidence indicates that UDCA should be considered as a component of comprehensive NAFLD therapy due to its ability to promote the elimination of excess free fatty acids from hepatocytes and, at the same time, exert a favorable effect on the associated cardiometabolic risk.
For citations: Ostroumova O.D., Kochetkov A.I., Plotnikova N.A., Dedovets E.K., Suglobova E.V. The role of ursodeoxycholic acid in the management of patients with non-alcoholic fatty liver disease and cardi-ometabolic multimorbidity: a review of current evidence. Pharmateca. 2026;33(4):271-281. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.4.271-281
Authors’ contribution: O.D. Ostroumova – review concept, scientific editing, and approval of the final version of the article. A.I. Kochetkov – literature search and analysis, article preparation, literature analysis, scientific editing, and approval of the final version of the article. N.A. Plotnikova – literature search and analysis, article preparation, bibliography, and approval of the final version of the article. All authors read and approved the final version of the manuscript.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Keywords
non-alcoholic fatty liver disease
cardiometabolic multimorbidity
type 2 diabetes mellitus
cardiovascular risk
ursodeoxycholic acid
About the Authors
Olga D. Ostroumova, Dr. Sci. (Med.), Professor, Head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education; Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Mos-cow, Russia; ostroumova.olga@mail.ru, ORCID: https://orcid.org/0000-0002-0795-8225, eLibrary SPIN: 3910-6585N.A. Plotnikova, Cand. Sci. (Med.), Associate Professor of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; na_tasah_90@mail.ru, ORCID: http://orcid.org/0000-0001-5454-9339
A.I. Kochetkov, Cand. Sci. (Med.), Associate Professor of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ak_info@list.ru, ORCID: https://orcid.org/0000-0001-5801-3742, eLibrary SPIN: 9212-6010
E.K. Dedovets, Candidate of the Academician M.S. Vovsi Department of Therapy and Polymorbid Pathology, Russian Medical Academy of Continuous Professional Education; Head of the Ultrasound Diagnostics Department, Scandinavian Health Center LLC, Moscow, Russia; ldedovets@bk.ru, ORCID: https://orcid.org/0009-0005-0017-833Х
E.V. Suglobova, Cand. Sci. (Med.), Cardiologist, Department of Cardiology, A.K. Eramishantsev City Clinical Hospital of the Moscow Department of Health, Moscow, Russia; ekaterina-vikt@mail.ru, ORCID: https://orcid.org/0000-0002-6566-070X
Similar Articles
